<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540852</url>
  </required_header>
  <id_info>
    <org_study_id>NIH-LAMMP-2002-2306</org_study_id>
    <nct_id>NCT00540852</nct_id>
  </id_info>
  <brief_title>Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy</brief_title>
  <official_title>Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beckman Laser Institute University of California Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chao Family Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimal management of patients with locally advanced breast cancer remains a complex&#xD;
      therapeutic problem. Newly diagnosed breast cancers in the United States with a higher&#xD;
      incidence in medically underserved areas. The optimal intensity and duration of neoadjuvant&#xD;
      chemotherapy still remains controversial due to the difficulty of evaluating response to&#xD;
      therapy. The goal would be to prevent over and under treatment of patients with neoadjuvant&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Researcher developed a diagnostic device called Diffuse Optical Spectroscopy Imaging is a&#xD;
      non-invasive optical technique that utilizes intensity-modulated, near-infrared light to&#xD;
      quantitatively measure optical properties in thick tissues.&#xD;
&#xD;
      Diffuse Optical Spectroscopy Imaging can images tissue hemoglobin , oxygen saturation, blood&#xD;
      volume fraction, water content, fat content and cellular structure. The measurements provide&#xD;
      quantitative optical property values that reflect changes in tissue perfusion, oxygen&#xD;
      consumption, and cell/matrix development.&#xD;
&#xD;
      There is no therapeutic benefit to the subject, especially none that might influence the&#xD;
      indication for the diagnostic procedure as indicated. However, information obtained may lead&#xD;
      to a new form of non-invasive imaging for the early detection of breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic tool</measure>
    <time_frame>12 weeks</time_frame>
    <description>Diffuse Optical Spectroscopy Imaging Breast Cancer Tumor in the response of Chemotherapy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic Tool</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diffuse Optical Spectroscopy Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diffuse Optical Spectroscopy Imaging</intervention_name>
    <description>Diffuse Optical Spectroscopy Imaging</description>
    <arm_group_label>Diagnostic Tool</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female non-pregnant and age greater than or equal to 21 years old but less than 75&#xD;
             years old&#xD;
&#xD;
          -  Diagnosed with breast cancer and will be receiving neoadjuvant chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female pregnant and age less than 21 years old and have no diagnosis of breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hsiang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Laser Institute University of California Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beckman Laser Institute University Of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Beckman Laser Institute and Medical Center</investigator_full_name>
    <investigator_title>David Hsiang, M.D., Division of Surgical Oncology</investigator_title>
  </responsible_party>
  <keyword>Breast cancer receiving chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

